Lesch KP, Widerlv E, Ekman R, Laux G, Schulte HM, Pfller H, Beckmann H
The 12-week mark aligns with what clinical GHK-Cu skin trials use as their primary endpoint, and the published results from those trials reflect what researchers running systematic protocols report: clear, documented improvement in skin architecture
Use sterile technique throughout handling to prevent contamination
188 These findings supported oxidative stress as a feature of AATD contributing to the risk of disease development late in life
Daily application at roughly the same time produces better results than sporadic use even at higher doses
Estrogen/HER2 receptor crosstalk in breast cancer: Combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer